[Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer].
Angiogenesis plays an important role in the pathogenesis of lung cancer. This process is caused by the imbalance between stimulating and inhibiting agents. VEGF is a key stimulator having a biologic effect via two different receptors of tyrosine kinase: VEGF-R1 and VEGF-R2. A soluble form of sVEGF-R1 is a negative regulator of VEGF activity. The serum concentrations of VEGF, sVEGF-R1 were assayed in 24 patients with NSCLC and 13 patients with SCLC and 10 healthy volunteers by means of ELISA method. The serum concentrations of VEGF were significantly higher in patients than in controls (p=0.016). The concentration of sVEGF-R1 was not significantly different in patients and controls. No statistically significant differences were established between the concentrations of VEGF, and sVEGF-R1 with regard to such clinical features, as: performance staging, clinical staging (stage III vs. stage IV) and histological pattern (NSCLC vs. SCLC). The significantly higher VEGF concentrations were reported in patients with the tumor of more than 7.5 cm in the diameter (p=0.027). Analyzing the influence of the response to treatment on the concentrations of parameters examined, a significant increase in VEGF concentration was demonstrated in the case of disease progression (p=0.034). The concentrations of sVEGF-R1 did not change after treatment. No correlation was found between parameters examined.